Bill Slattery, Jr.

Biotech IR & Communications Strategy*
Below Average Golfer
*Views are My Own

[Bill Slattery, Jr. @Slattery_Bill]

Proud to serve the ANCA-associated #vasculitis community and work with groups like the Vasculitis Foundation this #RareDiseaseDay

#MyCompany https://t.co/laNqexIVMx

[Bill Slattery, Jr. @Slattery_Bill]

#mycompany https://t.co/X6oDAnOXbM

[Bill Slattery, Jr. @Slattery_Bill]

@Gabolator @JerseyCity https://t.co/scvTGYZ3kW

[Bill Slattery, Jr. @Slattery_Bill]

@PetiteBeaute_xo @JerseyCity https://t.co/scvTGYZBau

[Bill Slattery, Jr. @Slattery_Bill]

@Preeemo2 https://t.co/x9uR7NBKR4

[Bill Slattery, Jr. @Slattery_Bill]

@Preeemo2 Yeah that makes sense it’s the general area where I saw the blue light explosion from

[Bill Slattery, Jr. @Slattery_Bill]

#MyCompany https://t.co/uCa1qz5J08

[Bill Slattery, Jr. @Slattery_Bill]

https://t.co/hFZUfE7HSU

[Bill Slattery, Jr. @Slattery_Bill]

Love to see this!

[Bill Slattery, Jr. @Slattery_Bill]

@MikeHuckman @fly2ohare I'm sure the data will be worth the wait! #ASCO22

[Bill Slattery, Jr. @Slattery_Bill]

Here at ChemoCentryx, patients are at the center of everything we do! Check out Kathy's story below. #VAM2022 https://t.co/5WtDirjH4B

[Bill Slattery, Jr. @Slattery_Bill]

Extra proud to be part of the ChemoCentryx team during this #VasculitisAwarenessMonth.

To those living with vasculitis and their caregivers, we're with you! #VAM2022 https://t.co/n9ES8FiFMF

[Bill Slattery, Jr. @Slattery_Bill]

Happy #RareDiseaseDay!! Excited to celebrate here at @ChemoCentryxInc!

[Bill Slattery, Jr. @Slattery_Bill]

It’s an absolute treat to work with Tom Schall, Susan Kanaya and the rest of the $CCXI team! A great day for patients, physicians and shareholders. Congratulations!

[Bill Slattery, Jr. @Slattery_Bill]

Welcome back @TigerWoods! #TheMasters #StillGotIt #Goosebumps

[PGA Tour @PGATour]

"That will be the greatest scene in golf. Forever."

"If that doesn't bring a tear to your eye, if you're a parent, you're not human."

[Gilead Sciences @GileadSciences]

Today, we and our partner @GalapagosNV announced top-line results from two Phase 3 studies evaluating an investigational therapy for #RheumatoidArthritis

[Bill Slattery, Jr. @Slattery_Bill]

JAKpot!!! Congrats to @GalapagosNV on incredible Phase 3 #filgotinib data in #RheumatoidArthritis. It has been a treat to work with you!!

#biopharma #pharma #biotechnology #arthritis #medicine #JAKinhibitor

[Lakefront Biotherapeutics @LakefrontBio]

We are excited to announce with @GileadSciences positive data from #filgotinib Finch 1 & 3 clinical trials.

This takes us one step closer to bringing our first medicine for #RheumatoidArthritis to market!

Read more here: https://t.co/e1qmePq9Ws

[Bill Slattery, Jr. @Slattery_Bill]

I'm proud to have the chance to work with the $CCXI team at such an exciting time in the Company's development! #RareDiseaseDay

[Bill Slattery, Jr. @Slattery_Bill]

@JohnCendpts @DealForma have been pulling together some interesting stats on Biotech dealmaking. 2018 was a monster year for $100M+ up-front deals w/ 24 deals for $7.1B cash & $28.4B milestones

[John D Carroll @JohnCendpts]

Special report by the numbers:
The $100M biotech club: Who’s in, and what’s it take to join the top-performing group of biopharmas?
https://t.co/yV7OSk7x2h